8-K: Cencora Reports Strong Q2 FY26 Results, Raises EPS Guidance

Cencora, Inc. announced robust fiscal 2026 second quarter results, with revenue up 3.8% year-over-year to $78.4 billion and adjusted diluted EPS increasing 7.5% to $4.75, leading to a raised full-year EPS outlook.

Summary

• Cencora reported second quarter fiscal year 2026 revenue of $78.4 billion, a 3.8% increase year-over-year.
• GAAP diluted EPS was $8.40, significantly up from $3.68 in the prior year quarter, largely due to a $1.1 billion gain from the OneOncology acquisition remeasurement.
• Adjusted diluted EPS rose 7.5% to $4.75 from $4.42 in the prior year quarter.
• The company raised its fiscal year 2026 adjusted diluted EPS guidance range to $17.65 - $17.90.
• Revenue growth was driven by a 2.9% increase in U.S. Healthcare Solutions and a 13.0% increase in International Healthcare Solutions.
• Gross profit increased 17.3% year-over-year to $3.6 billion.
• Operating expenses increased 20.9% to $2.4 billion, primarily due to the OneOncology acquisition.
• Cencora expects to repurchase $1 billion in shares by the end of calendar 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, significant adjusted EPS increase, and an upward revision of full-year guidance, indicating robust operational performance and positive future prospects.

Positives

• Revenue increased by 3.8% to $78.4 billion for the second quarter.
• Adjusted diluted EPS grew by 7.5% to $4.75.
• Full-year adjusted diluted EPS guidance was raised to $17.65 - $17.90.
• U.S. Healthcare Solutions revenue grew 2.9%, and International Healthcare Solutions revenue grew 13.0%.
• Gross profit increased by 17.3% to $3.6 billion.
• The company plans to repurchase $1 billion in shares by the end of 2026.
• Operating income as a percentage of revenue improved to 1.46% (GAAP) from 1.37% in the prior year.
• Adjusted operating income margin increased to 1.61% from 1.58%.

Negatives

• Operating expenses increased by 20.9% to $2.4 billion, largely due to the OneOncology acquisition.
• Net interest expense increased by 35.1% to $140.5 million due to financing for the OneOncology acquisition.
• Revenue growth in U.S. Healthcare Solutions was partially offset by a decline in manufacturer prices for certain brand pharmaceutical products and losses of a large mail order customer.
• Operating income in the 'Other' segment decreased by 1.3%.

Risks

• The company's results are subject to uncertainty and changes in circumstances, and forward-looking statements are not guarantees of future performance.
• Detailed risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and other SEC filings.
• The company faces risks related to the integration of acquisitions, such as the OneOncology acquisition.
• Fluctuations in manufacturer prices for pharmaceutical products can impact revenue.
• The company is exploring strategic alternatives for certain businesses within the 'Other' segment, which introduces uncertainty.

Future Outlook

Cencora has raised its fiscal year 2026 adjusted diluted EPS guidance to a range of $17.65 to $17.90. The company expects full-year revenue growth of 4% to 6%, U.S. Healthcare Solutions revenue growth of 4% to 6%, International Healthcare Solutions revenue growth of 8% to 10% (on a constant currency basis), and 'Other' segment revenue growth of 1% to 5%. Adjusted operating income is projected to grow 12% to 14%, with U.S. Healthcare Solutions expected to grow 14% to 16%. Adjusted free cash flow is anticipated to be approximately $3.0 billion.

Management Comments

• "Cencora delivered solid results in our second quarter as our team members continued to execute to meet the needs of our customers," said Robert P. Mauch, President and Chief Executive Officer of Cencora.
• "Our fiscal 2026 guidance reflects the strength of our business and focus on our strategy to create long-term value."
• "As we move into the second half of our fiscal year, we are pleased to have made progress on debt paydown and to be in a position to resume opportunistic share repurchases," Mr. Mauch continued.

Industry Context

StockSavvy.ai notes that Cencora's performance in the healthcare solutions and pharmaceutical distribution sector reflects ongoing demand for essential healthcare products and services, particularly in specialty areas and the growing GLP-1 market. The company's strategic acquisitions, like OneOncology, demonstrate a focus on expanding capabilities in high-growth segments.

Comparison to Industry Standards

• Cencora's reported revenue growth of 3.8% for the quarter is in line with or slightly above the general growth trends observed in the pharmaceutical distribution and healthcare services sector, which has seen moderate expansion.
• The adjusted diluted EPS growth of 7.5% indicates strong operational leverage and effective cost management, potentially outperforming some peers who may be facing margin pressures.
• The company's focus on specialty products and GLP-1s aligns with key industry trends, as these segments are experiencing significant growth and innovation.
• The acquisition of OneOncology positions Cencora to compete more effectively in the oncology support services market, a segment with high strategic importance and growth potential.

Legal Proceedings

• The company has ongoing litigation and opioid-related expenses, with a net credit of $86.8 million related to a derivative lawsuit settlement in the six months ended March 31, 2026.
• Gains from antitrust litigation settlements were noted in both the current and prior year quarters.

Stakeholder Impact

• Shareholders: Positively impacted by the raised EPS guidance, planned share repurchases, and a declared quarterly cash dividend of $0.60 per common share.
• Employees: Performance reflects successful execution by team members, potentially impacting incentive compensation.
• Customers: Continued execution to meet customer needs, with growth in key segments like U.S. and International Healthcare Solutions.
• Suppliers: Performance is influenced by manufacturer pricing and product sales, including specialty products and GLP-1s.

Next Steps

• Continue executing on the company's strategy to create long-term value.
• Progress on debt paydown.
• Resume opportunistic share repurchases.
• Attend the Bank of America Global Healthcare Conference (May 12-14, 2026).

Key Dates

Recommendation

The company demonstrated strong Q2 results with significant revenue growth and adjusted EPS increase, coupled with a raised full-year guidance. The planned share repurchases and dividend further enhance shareholder value. The strategic acquisition of OneOncology and focus on high-growth areas like GLP-1s position Cencora favorably for continued success in the evolving healthcare landscape.

Keywords

Cencora, 8-K, Earnings, Healthcare Solutions, Pharmaceuticals, Financial Results, EPS Guidance, Acquisition